CT-388 is an investigational once-weekly dual GLP-1/GIP receptor agonist being developed by Roche for obesity, type 2 diabetes, and related comorbidities. Phase II results in obesity showed substantial placebo-adjusted weight-loss effects and acceptable tolerability in the reported trial. The therapy remains in clinical development with Phase III obesity trials expected to start in 2026.
Roche Holding AG shares show potential undervaluation despite strong returns, with DCF models suggesting 59% upside. The pharmaceutical giant trades at P/E ratios below fair value estimates while maintaining solid financial performance and dividend growth. Recent pipeline developments and product innovations support long-term growth prospects.
Zealand Pharma's petrelintide achieved up to 10.7% average weight loss after 42 weeks in a 493-patient phase 2 trial, with placebo-like tolerability but lower efficacy than competing amylin drugs, causing Zealand shares to drop 34%.
Genentech announced positive Phase II results for CT-388, a dual GLP-1/GIP receptor agonist, showing 22.5% placebo-adjusted weight loss at 48 weeks in people with obesity. The treatment was well-tolerated with low discontinuation rates.
Roche announced positive phase II results for obesity drug petrelintide showing 10.7% weight reduction, while the FDA set a December 18 decision date for breast cancer drug giredestrant.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04838405 |
A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus |
COMPLETED | PHASE1 |
